About Dr. Douglas Berger Psychiatrist Tokyo


Dr. Douglas Berger, M.D., Ph.D., Meguro Counseling Center Director

Douglas Berger, M.D., Ph.D., is the Director of the Tokyo Meguro Counseling Center.  Fully bilingual in English and Japanese, he is an American board certified psychiatrist. Dr. Douglas Berger is a graduate of New York Medical College where he also completed a 4-year residency program in psychiatry. Dr. Berger’s Japanese qualifications include a Ph.D. from the University of Tokyo School of Medicine received for psychiatric research done while at the Tokyo University Department of Psychosomatic Medicine. He also completed a fellowship in Psychosomatic Medicine at the Albert Einstein College of Medicine. Now living in Tokyo, Douglas Berger has served on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry and licensed practicing U.S. physician.

Credential Verifications

Dr. Berger’s medical degree is from the United States, he is well-versed in the use of psychiatric medication and can guide the use of psychiatric medications integrated with psychotherapy through the physicians affiliated with his counseling practice (he does not directly practice medical care in Japan). Further information on Dr. Berger can be seen on his personal home page or the web site of the Meguro Counseling Center.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine.

Dr. Berger came to Japan as a medical exchange student and psychiatric researcher at the Tokai University School of Medicine on a research fellowship from the Matsumae International Foundation. He later returned to Japan to do further psychiatric research at the Tokyo University Department of Psychosomatic Medicine and the Tokyo Institute of Psychiatry. Dr. Berger speaks native-level Japanese and regularly conducts psychotherapy for mixed-cultural couples as well as the local Japanese community. This page lists Dr. Berger’s research activity, and this page is an archive of community education articles for the Tokyo Families Magazine written by Dr. Berger. Dr. Berger also works extensively with children as Director of the Tokyo Child & Adolescent Counseling Service. Dr. Berger is a legal permanent resident of Japan.

Feel free to contact Douglas Berger psychiatrist Tokyo with our contact form or the Home Page of the Meguro Counseling Center.

Brain changes in Mindfulness Based therapy was unblinded with only 16 subjects: https://t.co/CC4HlhldEi. If you look at many brain sections you may find something by chance, you need to half your p value for each section looked at, not done here. Us: https://t.co/kbQF1wSzGN

Tokyo Counseling Service on ADHD https://t.co/LPwy8DzMbB @YouTubeさんから

Antidepressants show efficacy under double blind vs blind placebo because blinding filters out hope and expectation. Neither randomization nor blind assessment can make up for the loss of control from no-blind, no placebo conditions. Us: https://t.co/tReJReVhnP

Blind placebo pills give 30% improvement in depression. In depression drug trials, “non-inferiority” is very easily obtained as everyone responds to the placebo effect. Superiority studies have a higher statistical hurdle than non-inferiority studies. Us: https://t.co/CcbDgs5z45.

Medication vs psychotherapy isn't valid in a clinical trial because you can't double blind all the arms. Its uncontrolled clinical data, endpoints are subjective, and medications require double blinding or blind placebo: https://t.co/WLIjKdXqXL.

Load More...

Douglas Berger Tokyo psychiatrist: Brain changes in Mindfulness Based therapy https://t.co/zpuzl9UBif

Douglas Berger Tokyo psychiatrist: Many therapy studies call themselves, “single-blind” https://t.co/uKasdYEwnY

Many therapy studies call themselves, “single-blind”, however, this when the subject is blind, not when assessors are blind. “Single-blind” is misleading the reader that there is some control of bias when there is not. Us: https://t.co/sooQBqR2nb.

Douglas Berger Tokyo psychiatrist: Antidepressants show efficacy under double blind https://t.co/mgUktrrS97

Douglas Berger Tokyo psychiatrist: Blind placebo pills give 30% improvement in depression https://t.co/DopRqQA0E0

Load More...